Physician profile
Brian A Saunders
NPI 1497723530
$1,581.31
in general payments reported to CMS, 2019-2025
8 companies · $723 in 2025
The $723 reported for 2025 was more than what 94% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $107 · 2023: $137 · 2024: $615 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $846.81 | 2022-2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $447.35 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Ethicon US, LLC | $114.29 | 2025 | Echelon Flex, Harmonic |
| Rhythm Pharmaceuticals, INC. | $75.42 | 2023-2024 | Imcivree, Imcivree |
| Currax Pharmaceuticals LLC | $33.47 | 2025 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $25.35 | 2023 | Gattex |
| Heron Therapeutics, INC. | $19.65 | 2025 | Zynrelef |
| Intra-Sana Laboratories | $18.97 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.